HMGB1 and neoplasm: Furthermore, pharmacologic inhibition of TLR4 with a cell permeable inhibitor or depletion of HMGB1 using neutralizing antibodies or HMGB1-specific siRNA reduced the efficacy of anti-tumour vaccination [11].